221 related articles for article (PubMed ID: 9439551)
1. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Matthews DR; Boland O
Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
[TBL] [Abstract][Full Text] [Related]
2. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Ligtenberg JJ; Reitsma WD; van Haeften TW
Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
[TBL] [Abstract][Full Text] [Related]
3. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
4. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
Portha B; Serradas P
Am J Med; 1991 Jun; 90(6A):15S-21S. PubMed ID: 1831320
[TBL] [Abstract][Full Text] [Related]
5. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
7. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
[TBL] [Abstract][Full Text] [Related]
8. Influence of gliclazide on glucose-stimulated insulin release in man.
van Haeften TW; Veneman TF; Gerich JE; van der Veen EA
Metabolism; 1991 Jul; 40(7):751-5. PubMed ID: 1870430
[TBL] [Abstract][Full Text] [Related]
9. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Della Casa L; del Rio G; Glaser B; Cerasi E
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
[TBL] [Abstract][Full Text] [Related]
10. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
Brogard JM; Pinget M; Dorner M
Curr Med Res Opin; 1984; 9(1):56-63. PubMed ID: 6373160
[TBL] [Abstract][Full Text] [Related]
11. The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Karunakaran S; Hammersley MS; Morris RJ; Turner RC; Holman RR
Metabolism; 1997 Dec; 46(12 Suppl 1):56-60. PubMed ID: 9439561
[TBL] [Abstract][Full Text] [Related]
12. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
[TBL] [Abstract][Full Text] [Related]
13. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
Vestergaard H; Lund S; Bjørbaek C; Pedersen O
Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of acute and chronic hypoglycemic action of gliclazide.
da Tos V; Maran A; Vigili de Kreutzenberg S; Marchetto S; Tadiotto F; Bettio M; Marescotti MC; Tiengo A; Del Prato S
Acta Diabetol; 2000; 37(4):201-6. PubMed ID: 11450504
[TBL] [Abstract][Full Text] [Related]
15. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
Della Casa L; del Rio G; Glaser B; Cerasi E
Am J Med; 1991 Jun; 90(6A):37S-45S. PubMed ID: 1872303
[TBL] [Abstract][Full Text] [Related]
16. Dose-response characteristics for arginine-stimulated insulin secretion in man and influence of hyperglycemia.
van Haeften TW; Voetberg GA; Gerich JE; van der Veen EA
J Clin Endocrinol Metab; 1989 Nov; 69(5):1059-64. PubMed ID: 2677037
[TBL] [Abstract][Full Text] [Related]
17. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
[TBL] [Abstract][Full Text] [Related]
18. Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
Serradas P; Bailbé D; Portha B
Diabetologia; 1989 Aug; 32(8):577-84. PubMed ID: 2528491
[TBL] [Abstract][Full Text] [Related]
19. Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus.
Shankar RR; Zhu JS; Baron AD
Metabolism; 1998 May; 47(5):573-7. PubMed ID: 9591749
[TBL] [Abstract][Full Text] [Related]
20. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]